GSK Jun 28, 2022 Ideaya Biosciences Selects Lead Pol Theta Helicase Inhibitor for Development With GlaxoSmithKline Jun 5, 2022 Rectal Cancer Patient Subset Shows Complete Response to Immunotherapy in Small Study Apr 13, 2022 Precision Cancer Consortium Launches With Bayer, GSK, Roche, Novartis as Founding Members Mar 23, 2022 LifeMine Therapeutics Nets $175M in Series C, Inks GSK Deal to Advance Genomically Informed Drugs Jan 25, 2022 Lyell Immunopharma's IND for T-Cell Receptor Therapy Gets FDA Clearance Jan 19, 2022 23andMe Details Genetically Informed Cancer Immunotherapy Development Plans Premium Jan 18, 2022 23andMe Gets $50M Payment as GSK Extends Companies' Drug Discovery Alliance Jan 14, 2022 Tempus, GSK Initiate Phase II Trial of Niraparib in PALB2-Mutated Tumors Oct 1, 2021 In Brief This Week: Gilead, Iovance, Eli Lilly, Merck KGaA, GlaxoSmithKline, Aspira Women's Health Aug 18, 2021 FDA Approves GlaxoSmithKline's Jemperli, Roche’s Ventana CDx for dMMR Solid Cancers Apr 22, 2021 FDA Approves GSK's Jemperli With Ventana CDx for dMMR Endometrial Cancer Feb 26, 2021 CHMP Recommends Approval of GSK's Dostarlimab in Endometrial Cancer Feb 8, 2021 FDA Accepts Ideaya Biosciences' IND for MAT2A Inhibitor Jan 21, 2021 Merck KGaA Discontinues Phase III Lung Cancer Trial of Bintrafusp Alfa Jan 13, 2021 JP Morgan Healthcare, Day 2: Eli Lilly, Pfizer, GlaxoSmithKline, Clovis Oncology, Invitae, and More Jan 11, 2021 Ideaya Biosciences Submits IND Application to Study MAT2A Inhibitor in Solid Tumors Dec 9, 2020 Nonprofit Friends of Cancer Research Launches Public-Private HRD Harmonization Project Nov 11, 2020 Adaptive Biotechnologies, GlaxoSmithKline Collaborate on MRD Testing Jun 4, 2020 PARP Inhibitor Response Markers Still Key Consideration in Ovarian Cancer Despite Broad Indications Premium Apr 30, 2020 GSK Gets Broad Zejula Indication in Ovarian Cancer; FDA Deems Myriad Genetics' Test Complementary Load More Breaking News Flare Therapeutics Raises $123M in Oversubscribed Series B Funding Round William Blair Initiates Coverage of MDxHealth With Outperform Rating White House Report Outlines Goals to Advance Genomic Research, Precision Therapy Development In Brief This Week: Fore Biotherapeutics, RayzeBio, Gilead Sciences, Atossa Therapeutics Bayer to Assess Nubeqa in High-Risk, Early-Stage Hormone-Sensitive Prostate Cancer BridgeBio Begins Phase I/II Study of SHP2 Inhibitor, Opdivo in KRAS-Mutant Solid Tumors